Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed extensive stage small cell lungcancer
• •No active CNS disease
• •* CNS metastasis allowed provided patient completed 1 course of CNS radiotherapy
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •More than 2 months
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Bilirubin normal
• •AST and ALT no greater than 2.5 times upper limit of normal (ULN)
• •PT and PTT no greater than 1.5 times ULN
• •Creatinine normal
• •Creatinine clearance at least 60 mL/min
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No prior allergic reactions to compounds of similar chemical or biologic composition to study agents
• •No other uncontrolled concurrent illness
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study compliance
• •See Disease Characteristics
• •At least 1 week since prior CNS radiotherapy and recovered
• •No prior radiotherapy to more than 25% of skeleton
• •No other prior anticancer therapy
• •No other concurrent investigational agents
• •No other concurrent anticancer therapy
• •No concurrent anticoagulation therapy
• •No concurrent combination antiretroviral therapy for HIV-positive patients